Composition for preventing and / or ameliorating cancer

Regulatory T cells expressing adiponectin, capable of autonomous proliferation and cell-in-cell interaction, provide a more effective cancer treatment by inducing apoptosis and suppressing cancer growth, addressing the limitations of humoral recombinant adiponectin in existing cancer therapies.

WO2024242123A1PCT designated stage expired Publication Date: 2024-11-28NAT UNIV CORP TOKAI NAT HIGHER EDUCATION & RES SYST +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018759
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-21
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current approaches using humoral recombinant adiponectin have shown limited effectiveness in inducing cell death of cancer cells, highlighting the need for a more potent method to prevent and improve cancer treatment.

Method used

A composition containing regulatory T cells that express adiponectin, which can exhibit a cell-in-cell phenomenon against cancer cells, even in the absence of adiponectin receptors, and can proliferate autonomously without thymic stromal cells, is developed.

Benefits of technology

The adiponectin-expressing regulatory T cells demonstrate enhanced proliferation and anticancer effects, including inducing apoptosis and suppressing cancer cell growth, particularly in triple-negative breast cancer and mesothelioma, with improved efficacy compared to traditional methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000031
    Figure 000031
  • Figure 000032
    Figure 000032
  • Figure 000033
    Figure 000033
Patent Text Reader

Abstract

The main purpose of the present disclosure is to provide a composition for preventing and / or ameliorating cancer. The inventors of the present invention have found that the above problem can be solved by regulatory T cells expressing adiponectin. According to the present disclosure, provided is a composition for preventing and / or ameliorating cancer, the composition containing regulatory T cells expressing adiponectin.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for preventing and / or ameliorating cancer

[0001] The present disclosure relates to compositions for preventing and / or ameliorating cancer.

[0002] Adiponectin is a type of adipocytokine secreted primarily from adipose tissue and is known to enhance insulin sensitivity and promote fatty acid oxidation. It has been reported that blood adiponectin levels are inversely correlated with BMI (Body Mass Index) and visceral fat mass, i.e., the higher the degree of obesity, the lower the blood adiponectin levels tend to be. Thus, adiponectin is closely related to obesity.

[0003] Recent studies have also suggested a relationship between adiponectin and cancer. For example, it has been reported that subjects with lower blood adiponectin levels may be at higher risk of developing cancer, and that adiponectin may suppress the development, proliferation, and metastasis of cancer cells through cell cycle arrest and apoptosis (Non-Patent Document 1).

[0004] Parida et al., "Adiponectin, Obesity, and Cancer: Clash of the Bigwigs in Health and Disease." Int. J. Mol. Sci. 2019, 20, 2519.Hug C. et al., "T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30 / adiponectin." Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10308-13.Toyooka KO, et al., "Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas." Cancer Res. 2001 Jun 1;61(11):4556-60.Prochazka M. et al., "The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency." Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3290-4.Hanamatsu Y. et al., "Adiponectin-expressing Treg cells in experimental thymic tumor model." Thorac Cancer. 2023 Feb;14(4):432-433.Hasegawa M. et al., "Tumor suppressor effect of an antibody on xenotransplanted sarcomatoid mesothelioma cells." Thorac Cancer. 2022 Sep;13(18):2566-2573.

[0005] In light of the above, the present inventors attempted to ameliorate cancer by using adiponectin, but as will be described later, liquid (not encapsulated in cells) recombinant adiponectin hardly induced cancer cell death.

[0006] Therefore, the main object of the present inventors was to provide a composition for preventing and / or ameliorating cancer, which utilizes adiponectin.

[0007] The present inventors have found that a composition for preventing and / or ameliorating cancer, which contains adiponectin-expressing regulatory T cells, can solve the above-mentioned problems. After further improvements, the present disclosure has been completed.

[0008] The present disclosure encompasses, for example, the subject matter described in the following paragraphs. Item 1. A composition for preventing and / or ameliorating cancer, comprising regulatory T cells expressing adiponectin. Item 2. The composition according to Item 1, wherein the regulatory T cells exhibit cell-in-cell activity against cancer cells. Item 3. The composition according to Item 1 or 2, wherein the regulatory T cells express HMW adiponectin. Item 4. The composition according to any one of Item 1 to 3, wherein the cancer has a reduced expression level of an adiponectin receptor. Item 5. The composition according to Item 4, wherein the adiponectin receptor is T-cadherin. Item 6. The composition according to any one of Item 1 to 5, wherein the cancer is at least one selected from the group consisting of breast cancer, mesothelioma, bladder cancer, and intraperitoneal disseminated cancer. Item 7. The composition according to any one of Item 1 to 5, wherein the cancer is breast cancer and / or mesothelioma. Item 8. The composition according to any one of Item 1 to 5, wherein the cancer is triple-negative breast cancer. Item 9. Item 10. The composition according to any one of Items 1 to 8, which is a pharmaceutical composition. Item 10. A method for producing adiponectin-expressing regulatory T cells that can proliferate in a culture system in the absence of thymic stromal cells, comprising the steps of: (A) co-culturing adiponectin-expressing regulatory T cells with thymic stromal cells; and (B) co-culturing the adiponectin-expressing regulatory T cells with thymic stromal cells, while reducing the ratio of the thymic stromal cells to the regulatory T cells at the start of the co-culture compared to the start of the previous co-culture. Item 11. A method for treating cancer, comprising administering a therapeutically effective amount of adiponectin-expressing regulatory T cells to a subject in need thereof. Item 12. Use of adiponectin-expressing regulatory T cells for the manufacture of a composition for preventing and / or ameliorating cancer. Item 13. A composition containing adiponectin-expressing regulatory T cells for use in treating cancer.

[0009] According to the technology of the present disclosure, there are provided a composition for preventing and / or ameliorating cancer using adiponectin, a method for producing regulatory T cells that express adiponectin, and the like.

[0010] Micrographs of cells cultured in Experimental Example 1-1 are shown. The round cells indicated by the arrowheads are T cells, and the spindle-shaped cells indicated by the arrows are thymic stromal cells. Figures 2a-c show the results of Experimental Example 1-2. Figure 2a shows the results of a control not incubated with antibody. Figure 2b shows the results after antibody incubation, before fractionation (pre-sort), and Figure 2c shows the results after fractionation (post-sort). Figures 2d and 2e show the results of Experimental Example 1-3. Figure 2d shows the results of nuclear staining with DAPI, and Figure 2e shows the results of staining with DAPI (blue), fluorescently labeled rabbit anti-adiponectin antibody (green), and fluorescently labeled mouse anti-FOXP3 antibody (red). In Figures 2d and 2e, the bars indicate 20 μm. Figure 2f shows the results of Experimental Example 1-4. The numbers to the left of the lanes indicate molecular weight (kDa), and the arrows indicate HMW adiponectin expression. Figure 4a shows micrographs of adiponectin-expressing Treg cells capable of autonomous proliferation even in the absence of thymic stromal cells, obtained in Test Example 2-1. Figure 4b shows the results of Test Example 2-2. Figure 4a shows the results of detecting apoptosis using chromatin DNA fragmentation at the nucleosomal unit (185 bp) for autonomously proliferating adiponectin-expressing Treg cells (left lane) and Treg cells that can proliferate only in coculture with thymic stromal cells (right lane). Figure 4b shows the results of detecting apoptosis using FITC-labeled annexin V and propidium iodide (PI) for autonomously proliferating adiponectin-expressing Treg cells (left) and Treg cells that can proliferate only in coculture with thymic stromal cells (right). In each graph, the plots in the lower left region represent live cells, the plots in the lower right region represent cells in the early apoptotic stage, and the plots in the upper right region represent cells in the late apoptotic stage. The plots in the upper left region represent cells that have undergone necrosis. The results of Test Example 2-3 are shown. The dashed line shows the results of the culture proliferation of autonomously proliferating adiponectin-expressing Treg cells, and the solid line shows the results of the proliferation of Treg cells that can only proliferate in a co-culture system with thymic stromal cells. The vertical axis of the graph shows the number of Treg cells, the horizontal axis shows the time elapsed since the start of culture, and the error bars show the standard deviation. The results of Test Example 2-4 are shown.Figure 6a shows the results for the autonomously proliferating adiponectin-expressing Treg cells obtained in Test Example 2-1, and Figure 6b shows the results for the Treg cells that can proliferate only in a co-culture system with thymic stromal cells obtained in Test Example 1-1. The bar indicates 20 μm. Adiponectin expression (green fluorescence) was higher in the autonomously proliferating adiponectin-expressing Treg cells than in the Treg cells that can proliferate only in a co-culture system. The results of Test Example 2-5 are shown. Lane 1 shows the control, lane 2 shows the autonomously proliferating adiponectin-expressing Treg cells obtained in Test Example 2-1, and lane 3 shows the diponectin-expressing Treg cells selected from the co-culture system. Uniform HMW diponectin is produced in lane 2. The results of Test Example 3-2 are shown. Figure 8a shows the results at an adiponectin concentration of 0 μg / mL (control), Figure 8b shows the results at 0.05 μg / mL, Figure 8c shows the results at 0.5 μg / mL, and Figure 8d shows the results at 5 μg / mL. The large numbers in each figure indicate the percentage of apoptotic cells among the evaluated cells. The results of Test Example 4 are shown. Lane 1 shows the lobular carcinoma cell line MDA-MB-330, lane 2 shows the triple-negative breast cancer cell line MDA-MB-231, lane 3 shows the triple-negative breast cancer cell line MDA-MB-157, and lane 4 shows the luminal A breast cancer cell line MCF-7. The * in lane 3 indicates a very faint band of 105 kDa T-cadherin, and the bands around 31 kDa in each lane indicate GAPDH (loading control). Figures 10a-d show the results of Test Example 5-2. Figure 10a shows MDA-MB-157 cells before co-culture, Figures 10b and 10c show images from different fields 16 hours after the start of co-culture, and Figure 10d shows an image 64 hours after the start of co-culture. Figures 10e-g show the results of Test Example 5-3. The arrowhead in Figure 10e indicates adhesion of adiponectin-expressing Treg cells to MDA-MB-157 cells, and the arrow indicates cytoplasmic integration of adiponectin-expressing Treg cells with MDA-MB-157 cells. Figure 10f shows a horizontal intracellular image, and Figure 10g shows a vertical intracellular image of the same subject as Figure 10f. Figures 10h and 10i show the results of Test Example 5-4.The arrows indicate the uptake of adiponectin-expressing Treg cells into MDA-MB-231 cells. The results of Test Example 6 are shown. The results for the control group are shown in Figure 11a, and the results for the group injected with adiponectin-expressing Treg cells are shown in Figure 11b. In Figures 11a and 11b, the arrows indicate intraperitoneal mesothelioma tumors. A representative example from the control group is shown in Figure 11c, and a representative example from the group injected with adiponectin-expressing Treg cells is shown in Figure 11d. In Figure 11c, the arrow indicates a mesothelioma nodule. Figure 11e shows a histological diagram of a mesothelioma nodule excised from the control group. The upper image in Figure 11e is an HE-stained specimen of a mesothelioma nodule from the control group, and the lower image is an enlarged version. As shown in Figure 11e, vigorous infiltration and proliferation of the mesothelioma nodule into the surrounding striated muscle tissue was observed. These mesothelioma nodules, which showed robust proliferation potential, were observed in the control group shown in Figures 11a and 11c, but were hardly observed in the groups injected with adiponectin-expressing Treg cells shown in Figures 11b and 11d.

[0011] Each embodiment included in the present disclosure will be described in more detail below. The present disclosure preferably includes, but is not limited to, a composition for preventing and / or ameliorating cancer, which contains adiponectin-expressing regulatory T cells, and a method for producing adiponectin-expressing regulatory T cells. The present disclosure includes all of the disclosures herein that are recognizable to a person skilled in the art.

[0012] Hereinafter, the composition encompassed by the present disclosure may be referred to as the "composition of the present disclosure." Furthermore, the adiponectin-expressing regulatory T cells may be referred to as the "regulatory T cells of the present disclosure," "Treg cells of the present disclosure," or the like.

[0013] Regulatory T cells (sometimes referred to as Treg cells or simply Treg in the present disclosure) are a type of T cell known to regulate immune responses in the immune system and prevent overreactions such as autoimmune diseases and allergic reactions. In the present disclosure, Treg cells refer to T cells that express FOXP3 protein in the nucleus. Although not particularly limited, the Treg cells contained in the composition of the present disclosure are preferably CD4 and / or CD25 positive, and more preferably CD4 and CD25 positive.

[0014] The Treg cells of the present disclosure express adiponectin. Adiponectin is a protein also known as Acrp30, apM1, GBP28, AdipoQ, etc., which has a collagen-like domain at the N-terminus and a globular domain at the C-terminus, with a monomeric molecular weight of approximately 30 kDa. As mentioned above, adiponectin is primarily secreted from adipocytes, but it has also been reported to be secreted from bone marrow, osteoblasts, fetal tissue, muscle cells, cardiac muscle cells, salivary gland epithelial cells, etc.

[0015] The Treg cells of the present disclosure are not particularly limited in origin, as long as they express adiponectin. For example, adiponectin-expressing Treg cells may be selected from Treg cells derived from living organisms. Alternatively, adiponectin-expressing Treg cells may be obtained by introducing a construct encoding a sequence for adiponectin expression into Treg cells that do not express adiponectin. Furthermore, adiponectin-expressing Treg cells may be obtained by differentiating adiponectin-expressing T cell precursors into Treg cells.

[0016] More specifically, a method for obtaining adiponectin-expressing Treg cells includes, for example, removing a thymic tumor, culturing the tumor cells, and then fractionating the T cells using CD4 positivity and / or CD25 positivity as an indicator. Thymic tumors obtained from, for example, non-obese diabetic / severe combined immunodeficiency (NOD / SCID) mice can be used. The presence of Treg cells in the obtained cells can be confirmed using FOXP3 expression as an indicator, and fractionation can be performed using FOXP3 positivity as an indicator to increase the proportion of Treg cells among the obtained cells. Adiponectin expression can be confirmed in the obtained cells, and fractionation can be performed using adiponectin expression as an indicator to increase the proportion of adiponectin-expressing Treg cells among the obtained cells.

[0017] Organisms from which the Treg cells of the present disclosure are derived include, for example, humans and non-human mammals (e.g., rats, mice, rabbits, cows, pigs, dogs, cats, sheep, monkeys, etc.).

[0018] Adiponectin exists in vivo in a variety of isoforms, ranging from trimers to high molecular weight (HMW) multimers, each of which has been reported to have different activities and functions. For example, trimers and hexamers of adiponectin have been suggested to be involved in regulating food intake, while HMW multimers of adiponectin (sometimes referred to as HMW adiponectin in this disclosure) have been suggested to be primarily involved in insulin sensitivity, hepatic gluconecine synthesis, and other metabolic regulation. Adiponectin isoforms are thought to be determined by intracellular processes such as posttranslational modification, and are not thought to undergo interconversion after extracellular secretion (Non-Patent Document 1).

[0019] In the technology of the present disclosure, the adiponectin isoform is not particularly limited as long as the effects of the present disclosure are achieved, and any isoform such as a monomer, trimer, hexamer, or HMW multimer may be used. However, a hexamer or HMW multimer that has the ability to bind to T-cadherin is preferred, and an HMW multimer is more preferred.

[0020] In the present disclosure, the term "HMW adiponectin" refers to an adiponectin multimer with a molecular weight of 190 kDa or greater. In this regard, the molecular weight of HMW adiponectin is not particularly limited, but may be, for example, 190 to 600 kDa, preferably 200 to 500 kDa, and more preferably 240 to 400 kDa. The upper or lower limit of the molecular weight of HMW adiponectin may be 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, 420, 440, 460, 480, 500, 520, 540, 560, 580, or 600 kDa.

[0021] AdipoR1, AdipoR2, and T-cadherin (sometimes called H-cadherin or cadherin-13) have been identified as adiponectin receptors. Among these, T-cadherin has been reported to be a receptor for hexameric and HMW adiponectin (Non-Patent Document 2). T-cadherin is expressed on the cell membrane surface and has an adiponectin-binding site in its extracellular domain.

[0022] Cases have been reported in which the expression level of adiponectin receptors is reduced in cancer cells. It has been suggested that the reduced expression level of adiponectin receptors is due to abnormal methylation in the promoter region of the adiponectin receptor gene (Non-Patent Document 3). Although not particularly limited, the composition of the present disclosure is preferably used for cancers in which the expression level of adiponectin receptors is reduced, and particularly preferably used for cancers in which the expression level of T-cadherin is reduced.

[0023] In the present disclosure, a decrease in the expression level of adiponectin receptor refers to a decrease in the expression level of normal (i.e., functional) adiponectin receptor when comparing cancer cells to which the composition of the present disclosure is applied with normal cells from the tissue from which the cancer cells originate. Therefore, even if a considerable amount of abnormal (i.e., functionally defective) adiponectin receptor is expressed in cancer cells, if the expression level of the normal adiponectin receptor is lower than that in normal cells, it is determined that the expression level of the adiponectin receptor is decreased. The term "expression level" includes both the amount of transcription product and the amount of translation product.

[0024] The degree of reduction in the expression level of adiponectin receptors may be, for example, 3 / 4 or 2 / 3 or less, preferably 1 / 2, 1 / 3, or 1 / 4, more preferably 1 / 5, 1 / 6, 1 / 7, 1 / 8, 1 / 9, or 1 / 10, even more preferably 1 / 20, 1 / 25, 1 / 30, 1 / 40, 1 / 50, 1 / 60, 1 / 70, 1 / 80, 1 / 90, or 1 / 100, and particularly preferably below the detection limit, when compared with the normal cells.

[0025] The decrease in the expression level of adiponectin receptors can be determined by a conventionally known method or a method that can be easily derived from a conventionally known method, such as reverse transcription quantitative PCR (RT-qPCR), RNA-seq, Western blotting, immunohistochemical staining, etc.

[0026] The Treg cells of the present disclosure can preferably exhibit the cell-in-cell phenomenon toward cancer cells. The cell-in-cell phenomenon refers to the phenomenon in which one cell is incorporated into another cell. That is, the Treg cells of the present disclosure can preferably be incorporated into cancer cells.

[0027] The compositions of the present disclosure are suitable for use in the prevention, amelioration, treatment, etc. of cancer. In the present disclosure, the term "cancer prevention" includes preventing the onset of cancer by applying the composition to a subject at a stage before the cancer is diagnosed, and preventing cancer metastasis by applying the composition to tissues in a subject diagnosed with cancer where cancer has not yet been found. In the present disclosure, the terms "cancer improvement" or "cancer treatment" include suppressing the progression of cancer, halting the progression of cancer, suppressing the proliferation of cancer cells, killing cancer cells, reducing the number of cancer cells, reducing tumor volume, and preventing cancer metastasis by applying the composition to a subject diagnosed with cancer. Furthermore, in the present disclosure, the term "anticancer effect" includes the effect of preventing, ameliorating, and treating cancer.

[0028] In the present disclosure, the term "cancer" encompasses carcinoma, neoplasm, and malignant tumor. Examples of cancer include breast cancer, mesothelioma, bladder cancer, intraperitoneal disseminated cancer, lung cancer, colorectal cancer, gastric cancer, soft tissue sarcoma, osteosarcoma, brain tumor, neuroblastoma, leukemia, lymphoma, liver cancer, kidney cancer, prostate cancer, retinoblastoma, ciliary body tumor, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, malignant soft tissue tumor, chondrosarcoma, renal cell carcinoma, ovarian cancer, uterine cancer, and cervical cancer.

[0029] The cancer to which the composition of the present disclosure is applicable is preferably at least one selected from the group consisting of breast cancer, mesothelioma, bladder cancer, and intraperitoneal disseminated cancer, and more preferably breast cancer and / or mesothelioma. Disseminated cancer refers to a state in which cancer cells have metastasized and spread to a location distant from the primary site. Intraperitoneal disseminated cancer refers to a state in which cancer cells have spread within the abdominal cavity and metastasized to organs present in the abdominal cavity, such as the stomach, small intestine, large intestine, liver, and pancreas, as well as to the peritoneal wall and peritoneal surface.

[0030] The composition of the present disclosure can be particularly suitably applied to triple-negative breast cancer, a type of breast cancer. Triple-negative breast cancer refers to breast cancer that is not positive for any of the estrogen receptor, progesterone receptor, and HER2 receptor (i.e., triple-negative). When at least one selected from the estrogen receptor, progesterone receptor, and HER2 receptor is positive, hormone therapy, targeted therapy, and the like are effective. However, in triple-negative breast cancer, which is negative for these receptors, general hormone therapy and targeted therapy are ineffective. Triple-negative breast cancer is considered to be biologically more malignant than other types of breast cancer.

[0031] As described below, the composition of the present disclosure is thought to improve cancer through a different mechanism of action than the estrogen receptor, progesterone receptor, and HER2 receptor, and therefore may be suitable for use in triple-negative breast cancer, for which general hormone therapy or targeted therapy is ineffective.

[0032] The composition of the present disclosure may be, for example, but is not limited to, a pharmaceutical composition.

[0033] The compositions of the present disclosure can be applied to, for example, humans and non-human mammals (e.g., rats, mice, rabbits, cows, pigs, dogs, cats, sheep, monkeys, etc.), with humans being preferred.

[0034] The method of application of the composition of the present disclosure is not particularly limited as long as the desired effect is achieved. For example, the composition may be administered directly into a lesion by injection, or may be administered by injection or infusion into a vein, an artery, an intraperitoneal cavity, an intramuscular cavity, a subcutaneous cavity, an intrapleural cavity, or the like, or may be administered by perfusion via a catheter. Of these, direct administration into a lesion by injection is preferred.

[0035] The application frequency of the composition of the present disclosure is not particularly limited. For example, it may be applied once or multiple times a day, once or multiple times a week, once or multiple times a month, or once or multiple times a year. The application period of the composition of the present disclosure is also not particularly limited, as long as the effects of the present disclosure are achieved. Furthermore, the dosage of the composition of the present disclosure is also not particularly limited, as long as the effects of the present disclosure are achieved. The application frequency, application period, and dosage can be adjusted appropriately by those skilled in the art depending on the condition of the subject, the course of treatment, etc.

[0036] The composition of the present disclosure may be optionally combined with other pharmaceutical compositions and / or treatment methods, etc., that are applied to a subject with cancer. When the composition of the present disclosure is combined with other pharmaceutical compositions and / or treatment methods, etc., they may be applied to a subject simultaneously, or may be applied separately at any time.

[0037] In addition to the Treg cells of the present disclosure, the compositions of the present disclosure may contain pharmaceutically acceptable bases, carriers, excipients, diluents, solubilizers, emulsifiers, preservatives, pH adjusters, adjuvants, etc., either alone or in combination of two or more.

[0038] Examples of preservatives include parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben, sodium benzoate, phenoxyethanol, alkyldiaminoethylglycine hydrochloride, etc. The preservatives may be used alone or in combination of two or more.

[0039] Examples of pH adjusters include citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid, and chemically possible salts thereof, as well as sodium hydroxide, potassium hydroxide, etc. pH adjusters can be used alone or in combination of two or more so that the pH of the composition is in the range of 4 to 8, preferably 5 to 7.

[0040] The method for preparing the composition of the present disclosure is not particularly limited as long as the effects of the present disclosure are achieved. For example, the composition can be prepared according to a method known in the art. More specifically, the composition can be prepared by mixing the Treg cells of the present disclosure and other components with sterile distilled water.

[0041] As mentioned above, cases have been reported in which the expression level of adiponectin receptors is reduced in cancer cells. Without wishing to be bound by theory, in the technology of the present disclosure, adiponectin is encapsulated in Treg cells, and therefore it is thought that adiponectin is taken up into cancer cells by the cell-in-cell phenomenon regardless of the presence or absence of adiponectin receptors, thereby exerting an anticancer effect.

[0042] The present disclosure also encompasses a method for producing regulatory T cells that can proliferate in a culture system that does not contain thymic stromal cells and that express adiponectin. Hereinafter, this production method may be referred to as the "production method of the present disclosure." Furthermore, in the present disclosure, the ability to proliferate in a culture system that does not contain thymic stromal cells may be referred to as "capable of autonomous proliferation" or "autonomously proliferating," etc.

[0043] As will be described later, it has been reported that adiponectin-expressing regulatory T cells isolated in Non-Patent Document 5 undergo cell death (apoptosis) in an environment without thymic stromal cells. The production method disclosed herein makes it possible to establish adiponectin-expressing Treg cells that can proliferate even in an environment without thymic stromal cells.

[0044] Adiponectin-expressing Treg cells that can proliferate even in the absence of thymic stromal cells are preferable compared to Treg cells that can proliferate only in a co-culture system with thymic stromal cells, in that they do not require a step of separation from thymic stromal cells before use (e.g., application to a subject). Furthermore, as described below, adiponectin-expressing Treg cells capable of autonomous proliferation can have excellent properties in terms of proliferation efficiency and uniformity of expressed adiponectin isoforms, and are therefore also preferable from this viewpoint.

[0045] The production method of the present disclosure includes: (A) co-culturing adiponectin-expressing regulatory T cells and thymic stromal cells; and (B) co-culturing the adiponectin-expressing regulatory T cells and the thymic stromal cells while reducing the ratio of the thymic stromal cells to the regulatory T cells at the start of the co-culture compared to the start of the previous co-culture.

[0046] In step (B), the manner in which the ratio of thymic stromal cells to Treg cells is reduced from the ratio at the start of the previous co-culture is not particularly limited, as long as the desired effect is achieved. For example, if the first co-culture is initiated at a ratio of 1 thymic stromal cell to 100 adiponectin-expressing Treg cells, the second co-culture may be initiated at a ratio of 1 thymic stromal cell to 1,000 adiponectin-expressing Treg cells. Thymic stromal cells are adherent to the culture dish, while adiponectin-expressing Treg cells are non-adherent (i.e., floating) to the culture dish. Therefore, a thymic stromal cell fraction adhering to the dish can be obtained by aspirating the culture medium from the co-culture system, and an adiponectin-expressing Treg cell fraction floating in the culture medium can be obtained by centrifuging the culture medium. The process from the initiation of co-culture to the isolation of Treg cells from the co-culture system after any period of co-culture is counted as one co-culture.

[0047] As long as the desired effect is obtained, step (B) may be performed once or multiple times. When performed multiple times, it may be performed, for example, 1 to 10 times, preferably 1 to 5 times. The upper or lower limit of the range may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times.

[0048] The ratio of thymic stromal cells to Treg cells at the start of each co-culture is not particularly limited, as long as it is lower than the ratio of thymic stromal cells to Treg cells at the start of the previous co-culture. For example, the ratio may be 1 to 100,000 adiponectin-expressing Treg cells per 1 thymic stromal cell, preferably 5 to 10,000, and more preferably 10 to 1,000. The upper or lower limit of the range may be 1, 2, 5, 7, 10, 20, 50, 70, 100, 200, 500, 700, 1,000, 2,000, 5,000, 7,000, 10,000, 20,000, 50,000, 70,000, or 100,000.

[0049] The co-culture periods in steps (A) and (B) are not particularly limited and may be, for example, 1 to 30 days, preferably 5 to 10 days, from the start of co-culture. The upper or lower limit of this range may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days, or 1, 2, or 3 weeks. Furthermore, the co-culture periods for each round may be the same or different.

[0050] One embodiment of the manufacturing method of the present disclosure is described below, but the manufacturing method of the present disclosure is not limited to the following example. A cell population containing a mixture of Treg cells and thymic stromal cells is cultured in a Petri dish (step (A)). The culture medium is aspirated from the culture dish to obtain a fraction of thymic stromal cells adhering to the dish. The aspirated culture medium is then centrifuged to obtain an adiponectin-expressing Treg cell fraction. Next, co-culture is initiated at a ratio of 1:100 of the isolated adiponectin-expressing Treg cells to 1 thymic stromal cell. One week after the initiation of co-culture, thymic stromal cells and adiponectin-expressing Treg cells are separated using the method described above (step (B) 1st round). Co-culture is initiated at a ratio of 1:10,000 of the isolated adiponectin-expressing Treg cells to 1 thymic stromal cell. One week later, the culture medium is recovered and centrifuged to obtain adiponectin-expressing Treg cells (step (B) 2nd round).

[0051] In addition to steps (A) and (B), the production method of the present disclosure preferably further comprises step (C): culturing the adiponectin-expressing Treg cells isolated after co-culture without the presence of thymic stromal cells (i.e., the adiponectin-expressing Treg cells alone) to confirm their ability to proliferate autonomously. If the ability of adiponectin-expressing Treg cells to proliferate autonomously is not confirmed in step (C), step (B) may be repeated until the ability to proliferate autonomously is confirmed.

[0052] In the technology of the present disclosure, the method for culturing cells, for example, the medium, culture vessel, culture conditions, culture period, passaging method, etc., is not particularly limited, and any conventionally known method or a method that can be easily derived from a conventionally known method can be employed.

[0053] The medium may be, for example, a conventionally known basal medium supplemented with optional components that can be added to the medium. Examples of known basal media include Dulbecco's modified MEM medium (DMEM medium), Ham's F12 medium, DMEM / F12 medium, IMDM medium, and EMEM medium. Optional components that can be added to the medium include, for example, fetal bovine serum (FBS), bovine serum albumin (BSA), transferrin, insulin, ethanolamine, fatty acids, collagen precursors, trace elements, 2-mercaptoethanol, thioglycerol, lipids, amino acids, vitamins such as ascorbic acid, growth factors such as EGF, antibiotics such as penicillin and streptomycin, antioxidants, buffers, and inorganic salts. The optional components that can be added to the medium may be used alone or in combination of two or more. In the present disclosure, the components contained in the medium and their amounts are not particularly limited as long as they do not inhibit cell growth. Furthermore, a medium of the same composition may be used throughout the culture period, or it may be replaced with a medium of a different composition at any time. A preferred medium for culturing the Treg cells of the present disclosure is, for example, DMEM medium containing 10% fetal bovine serum (FBS).

[0054] The conditions for culturing the cells are not particularly limited as long as cell growth is not inhibited. The culture temperature can be, for example, about 20°C to 45°C, preferably about 30°C to 40°C, more preferably about 35°C to 40°C, and particularly preferably about 37°C. The CO2 concentration is also not particularly limited and may be, for example, about 5%.

[0055] Depending on the state of the cells, passage may be performed as appropriate. For example, the cells may be passaged when they grow and the cell occupancy rate (confluency) reaches about 80% or more. Furthermore, depending on the state of the cells, medium replacement may be performed as appropriate. The medium after medium replacement may have the same composition as the medium before medium replacement, or may have a different composition.

[0056] In this specification, the term "comprising" includes "essentially consisting of" and "consisting of" in addition to "containing." Furthermore, the present disclosure encompasses all arbitrary combinations of the constituent elements described in this specification.

[0057] Furthermore, the various characteristics (properties, values, functions, etc.) described in each embodiment of the present disclosure above may be combined in any way to identify the subject matter encompassed by the present disclosure. In other words, the present disclosure encompasses all subject matter consisting of any combination of the combinable characteristics described herein.

[0058] Hereinafter, the embodiments of the present disclosure will be described more specifically with reference to examples, but the embodiments of the present disclosure are not limited to the following examples.

[0059] Test Example 1. Isolation of adiponectin-expressing regulatory T cells. 1-1. 14-week-old non-obese diabetic / severe combined immunodeficiency (NOD / SCID) mice (strain name: NOD.CB17-Prkdc scid Thymic tumors were excised from NOD mice (J, Charles River Laboratories). These mice were created by crossbreeding a SCID mouse with a Prkdcscid mutation, and are a model mouse that combines the severe immunodeficiency caused by congenital T and B lymphocyte deficiencies of SCID mice with the genetic background of NOD mice, which exhibit reduced NK cell activity (Non-Patent Document 4).

[0060] The excised thymic tumor mass was broken down into small pieces and cultured in antibiotic-free DMEM medium containing 10% heat-inactivated fetal bovine serum (FBS). Culture was performed in a 35 mm dish at 37°C in a 5% CO2 incubator. A micrograph of the cultured cells is shown in Figure 1. In Figure 1, the round cells indicated by the arrowheads are T cells, and the spindle-shaped cells indicated by the arrows are thymic stromal cells.

[0061] 1-2. The cells obtained in Test Example 1-1 were subjected to fluorescent immunostaining using anti-CD4 and anti-CD25 antibodies to fractionate T cells. Specifically, the cells were incubated with phycoerythrin (PE)-conjugated rat anti-mouse CD4 antibody (SONY) and fluorescein isothiocyanate (FITC)-conjugated rabbit monoclonal anti-mouse CD25 antibody (Sino Biological Co., Ltd.), followed by fractionation using an SH800 cell analyzer (SONY). Figure 2a shows the results for the control group not incubated with antibodies; Figure 2b shows the results after antibody incubation (before fractionation, pre-sort); and Figure 2c shows the results after fractionation (post-sort).

[0062] 1-3. The CD4 and CD25 positive T cells fractionated in Test Example 1-2 were nuclear stained with DAPI (4',6-diamidino-2-phenylindole) and observed under a confocal laser scanning microscope (Leica). The results are shown in Figure 2d.

[0063] Furthermore, the T cells were immunostained with DAPI (blue), fluorescently labeled rabbit anti-adiponectin antibody (green) (GeneTex), and fluorescently labeled mouse anti-FOXP3 antibody (red) (Proteintech), and observed under a confocal laser scanning microscope (Leica). The results are shown in Figure 2e. In Figures 2d and 2e, the bars indicate 20 μm.

[0064] In Figure 2e, the pink color indicates the overlap of the blue immunostained nuclei and the red immunostained FOXP3. These results demonstrate that FOXP3 is expressed in the nuclei of the cells fractionated in Test Example 1-2, i.e., that these cells are regulatory T cells (Treg cells). Furthermore, as shown in green in Figure 2e, adiponectin was expressed in the cytoplasm of the Treg cells. The varying shades of green in Figure 2e indicate that the level of adiponectin expression in the Treg cells varies from cell to cell.

[0065] 1-4. Adiponectin was detected by Western blotting for the Treg cells fractionated in Test Example 1-2.

[0066] Specifically, cell lysates were electrophoresed on sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and then transferred to polyvinylidene fluoride membranes (Immobilon-P Transfer Membranes; Merck). The membranes were blocked with blocking milk (Megmilk Snow Brand) and incubated with rabbit anti-adiponectin antibodies. Immunodetection was performed using horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibodies (Cell Signaling Technology) and an ultrasensitive HRP luminescent substrate (TaKaRa Bio). Images were captured using an Invitrogen iBright 1500 gel imaging system (Thermo Fisher Scientific). After stripping the antibodies from the membranes, the membranes were incubated with anti-GAPDH antibodies (Merck) to assess input. The results are shown in Figure 2f. The numbers to the left of the lanes indicate molecular weights (kDa).

[0067] As indicated by the arrow in Figure 2f, HMW adiponectin with a molecular weight greater than 240 kDa was expressed in the Treg cells. In addition to HMW adiponectin, expression of adiponectins with various molecular weights was also confirmed. The band around 31 kDa in Figure 2f represents GAPDH (loading control).

[0068] Test Example 2. Establishment of autonomously proliferating adiponectin-expressing Treg cells It has been reported that adiponectin-expressing regulatory T cells isolated in Non-Patent Document 5 undergo cell death (apoptosis) in the absence of thymic stromal cells.

[0069] Therefore, the present inventors attempted to establish adiponectin-expressing Treg cells that are capable of autonomous proliferation even in an environment in which thymic stromal cells are not present.

[0070] 2-1. The present inventors gradually reduced the proportion of thymic stromal cells in a co-culture system of thymic stromal cells and adiponectin-expressing Treg cells, ultimately resulting in a state in which no thymic stromal cells were present.

[0071] Specifically, the cell population containing a mixture of Treg cells and thymic stromal cells obtained in Test Example 1-1 was first cultured in a petri dish. As described above, thymic stromal cells are adherent to the culture dish, while adiponectin-expressing Treg cells are non-adherent (i.e., floating) to the culture dish. After aspirating the culture medium from the culture dish, a thymic stromal cell fraction adhering to the dish was obtained. The aspirated culture medium was then centrifuged to obtain an adiponectin-expressing Treg cell fraction.

[0072] Next, co-culture was initiated at a ratio of 1 thymic stromal cell to 100 adiponectin-expressing Treg cells. One week after the initiation of co-culture, thymic stromal cells and adiponectin-expressing Treg cells were separated using the method described above, and then co-culture was initiated at a ratio of 1 thymic stromal cell to 10,000 adiponectin-expressing Treg cells. One week later, the culture medium was collected and centrifuged to obtain adiponectin-expressing Treg cells.

[0073] When the isolated adiponectin-expressing Treg cells were cultured for one week without the addition of thymic stromal cells, proliferation of the adiponectin-expressing Treg cells alone (i.e., autonomous proliferation) was confirmed (Figure 3).

[0074] All cell cultures were performed in a DMEM medium containing 10% fetal bovine serum (FBS) at 37°C in a 5% CO2 incubator.

[0075] 2-2. Adiponectin-expressing Treg cells capable of autonomous proliferation in the absence of thymic stromal cells (hereinafter referred to as autonomously proliferating adiponectin-expressing Treg cells) obtained in Test Example 2-1 and the Treg cells fractionated in Test Example 1-2 were seeded in DMEM medium containing 10% fetal bovine serum (FBS) and cultured for 72 hours in a 37°C, 5% CO2 incubator without the presence of thymic stromal cells. Apoptosis was detected using chromatin DNA fragmentation at nucleosome units (185 bp). Specifically, the presence or absence of DNA laddering was assessed using the Apoladder Ex kit (Takara Bio) according to the attached protocol. The results are shown in Figure 4a. Furthermore, the cells cultured in the absence of thymic stromal cells were mixed with FITC-labeled annexin V and propidium iodide (PI) (PromoCell GmbH), and the number of cells undergoing apoptosis was measured using a Guava® EasyCyte cell analyzer (Luminex). The results for the autonomously proliferating adiponectin-expressing Treg cells are shown in the left side of Figure 4b, and the results for the Treg cells fractionated in Test Example 1-2 are shown in the right side of Figure 4b. Of the four regions in each graph in Figure 4b, the plots in the lower left region represent live cells, the plots in the lower right region represent cells in the early apoptotic stage, and the plots in the upper right region represent cells in the late apoptotic stage.

[0076] As is clear from Figures 4a and 4b, the autonomously proliferating adiponectin-expressing Treg cells did not undergo apoptosis in an environment in which thymic stromal cells were not present, whereas the Treg cells fractionated in Test Example 1-2 were found to undergo apoptosis in an environment in which thymic stromal cells were not present.

[0077] 2-3. The proliferation rate of the autonomously proliferating adiponectin-expressing Treg cells obtained in Test Example 2-1 when cultured alone was compared with the proliferation rate of the Treg cells, which can proliferate only in a co-culture system with thymic stromal cells obtained in Test Example 1-1, in a co-culture system. Specifically, the number of Treg cells was counted at each time point using a hemocytometer. The number of autonomously proliferating adiponectin-expressing Treg cells was 3.5 x 10 at 24 hours after the start of culture.3 (standard deviation 1.0), 10.1 x 10 at 48 hours 3 The number of Treg cells, which can only proliferate in a co-culture system with thymic stromal cells, was 2.3 × 10 at 24 hours after the start of culture (standard deviation 2.2). 3 (standard deviation 0.8), 5.6 × 10 at 48 hours 3 The results are shown in Figure 5. The vertical axis of the graph shows the number of Treg cells, the horizontal axis shows the time elapsed since the start of culture, and the error bars show the standard deviation. The dashed line shows the results for autonomously proliferating adiponectin-expressing Treg cells, and the solid line shows the results for Treg cells that can proliferate only in a co-culture system with thymic stromal cells.

[0078] As is clear from Figure 5, it was found that the autonomously proliferating adiponectin-expressing Treg cells have a higher proliferation ability than Treg cells that can proliferate only in a co-culture system with thymic stromal cells.

[0079] 2-4. The autonomously proliferating adiponectin-expressing Treg cells obtained in Test Example 2-1 and the Treg cells capable of proliferation only in a coculture system with thymic stromal cells obtained in Test Example 1-1 were immunostained with DAPI (blue), fluorescently labeled rabbit anti-adiponectin antibody (green) (GeneTex), and fluorescently labeled mouse anti-FOXP3 antibody (red) (Proteintech) as in Test Example 1-3, and observed under a confocal laser scanning microscope (Leica). Figure 6a shows the results for the autonomously proliferating adiponectin-expressing Treg cells obtained in Test Example 2-1, and Figure 6b shows the results for the Treg cells capable of proliferation only in a coculture system with thymic stromal cells obtained in Test Example 1-1. The bars in Figures 6a and 6b indicate 20 μm.

[0080] As shown in Figure 6a, it was confirmed that adiponectin was expressed in most of the autonomously proliferating adiponectin-expressing Treg cells obtained in Test Example 2-1. On the other hand, as shown in Figure 6b, among the Treg cells that can proliferate only in a co-culture system with thymic stromal cells obtained in Test Example 1-1, adiponectin expression was limited to a portion of the Treg cells. These results demonstrate that when Treg cells that can proliferate only in a co-culture system with thymic stromal cells are used in the technology of the present disclosure, it is necessary to select those that express adiponectin in advance, whereas when autonomously proliferating adiponectin-expressing Treg cells are used, selection is not necessary.

[0081] 2-5. Western blotting was performed in the same manner as in Test Example 1-4 to detect adiponectin for the autonomously proliferating adiponectin-expressing Treg cells obtained in Test Example 2-1, adiponectin-expressing cells selected from Treg cells capable of proliferating only in a coculture system with thymic stromal cells obtained in Test Example 1-1 (hereinafter referred to as diponectin-expressing Treg cells selected from a coculture system), and thymus-derived cells that do not express adiponectin (control). The results are shown in Figure 7.

[0082] 7, lane 1 shows the control, lane 2 shows the autonomously proliferating adiponectin-expressing Treg cells obtained in Test Example 2-1, and lane 3 shows the diponectin-expressing Treg cells selected from the coculture system. As is clear from a comparison of the band patterns in lanes 2 and 3, HMW adiponectin of a uniform molecular weight was expressed in the autonomously proliferating adiponectin-expressing Treg cells, whereas HMW adiponectin of various molecular weights was expressed in the adiponectin-expressing Treg cells selected from the coculture system.

[0083] 2-6. Summary These experimental results demonstrate that by gradually decreasing the proportion of thymic stromal cells in a co-culture system of thymic stromal cells and adiponectin-expressing Treg cells, adiponectin-expressing Treg cells that do not undergo apoptosis (i.e., autonomously proliferating) can be obtained even in the absence of thymic stromal cells. Furthermore, it was found that autonomously proliferating adiponectin-expressing Treg cells have a higher proliferation capacity than Treg cells that can only proliferate in a co-culture system with thymic stromal cells. Furthermore, it was found that when autonomously proliferating adiponectin-expressing Treg cells are used in the technology disclosed herein, it is not necessary to select cells expressing adiponectin from a cell population in advance. Furthermore, it was found that the Treg cells express a uniform HMW adiponectin molecular weight.

[0084] Test Example 3. Examination of the effect of liquid recombinant adiponectin on triple-negative breast cancer 3-1. Triple-negative breast cancer cell line MDA-MB-157 (American Type Culture Collection) was cultured in DMEM medium containing high glucose (4500 mg / L) and 10% fetal bovine serum (FBS) at 37°C in a 5% CO2 incubator. MDA-MB-157 cells were thawed from a liquid nitrogen tank and used for testing within six months.

[0085] 3-2. Cultured MDA-MB-157 cells were mixed with eukaryotic recombinant human adiponectin (Recombinant Human Adiponectin / Acrp30 Protein, CF, R&D Systems) at a concentration of 0 to 5 μg / mL and incubated for 36 hours. Note that the eukaryotic recombinant human adiponectin is not encapsulated within cells and has a monomeric structure. In this disclosure, adiponectin that is not encapsulated within cells is referred to as "liquid" adiponectin.

[0086] After incubation, MDA-MB-157 cells were mixed with FITC-labeled annexin V and propidium iodide (PI) (PromoCell GmbH), and apoptosis was assessed using a Guava® EasyCyte cell analyzer (Luminex). Figure 8a shows the results at 0 μg / mL adiponectin concentration (control), Figure 8b shows the results at 0.05 μg / mL, Figure 8c shows the results at 0.5 μg / mL, and Figure 8d shows the results at 5 μg / mL. The large numbers in each figure indicate the percentage of apoptotic cells among the assessed cells.

[0087] As shown in Figure 8a–d, the percentage of apoptotic MDA-MB-157 cells increased in an adiponectin dose-dependent manner, but even at the highest concentration of 5 μg / mL adiponectin, less than 10% of the cells underwent apoptosis.

[0088] These results indicate that although liquid adiponectin can induce apoptosis in cancer cells, the efficiency of this induction is very low.

[0089] Test Example 4. Detection of T-cadherin in cancer cells Triple-negative breast cancer cell lines MDA-MB-157 and MDA-MB-231, lobular carcinoma cell line MDA-MB-330 (American Type Culture Collection), and luminal A breast cancer cell line MCF-7 (Japanese Collection of Research Biosources Cell Bank) were cultured in the same manner as in Test Example 3-1. Luminal A breast cancer is hormone receptor (estrogen receptor and / or progesterone receptor)-positive, HER2-negative breast cancer.

[0090] T-cadherin was detected for each cultured cell line by Western blotting. Specifically, cell lysates were electrophoresed on sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and then transferred to polyvinylidene fluoride membranes (Immobilon-P Transfer Membranes; Merck). The membranes were blocked with blocking milk (Megmilk Snow Brand) and incubated with anti-T-cadherin antibodies. Immunodetection was performed using horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibodies (Cell Signaling Technology) and an ultrasensitive HRP luminescent substrate (TaKaRa Bio). Images were captured using an Invitrogen iBright 1500 gel imaging system (Thermo Fisher Scientific). After stripping the antibodies from the membranes, the membranes were incubated with anti-GAPDH antibodies (Merck) to assess input. The results are shown in Figure 9. In FIG. 9, the numbers shown on the left indicate molecular weights (kDa).

[0091] In Figure 9, lane 1 represents the lobular carcinoma cell line MDA-MB-330, lane 2 represents the triple-negative breast cancer cell line MDA-MB-231, lane 3 represents the triple-negative breast cancer cell line MDA-MB-157, and lane 4 represents the luminal A breast cancer cell line MCF-7. A very faint T-cadherin band at 105 kDa (indicated by * in Figure 9) was observed in lane 3, but no T-cadherin band was observed in lanes 1, 2, and 4. The band around 31 kDa in Figure 9 represents GAPDH (loading control).

[0092] From the above results, it was revealed that expression of T-cadherin, a receptor for hexameric and HMW adiponectin, was hardly observed in the above cancer cell lines, or if observed, was very slight.

[0093] Test Example 5. Co-culture of adiponectin-expressing Treg cells and triple-negative breast cancer cells 5-1. The adiponectin-expressing Treg cells obtained in Test Example 2 were co-cultured with the triple-negative breast cancer cell line MDA-MB-157 or MDA-MB-231 described in Test Example 4. Specifically, the cells were cultured in a DMEM medium containing high glucose (4500 mg / L) and 10% fetal bovine serum (FBS) at 37°C in a 5% CO2 incubator.

[0094] 5-2. Figures 10a–d show time-lapse images taken with a CytoWatcher (ATTO) during coculture of adiponectin-expressing Treg cells and MDA-MB-157 cells. Figure 10a shows MDA-MB-157 cells before coculture. Figures 10b and 10c show images from different fields of view taken 16 hours after the start of coculture. Figure 10d shows an image taken 64 hours after the start of coculture. As indicated by the arrows in Figures 10b and 10c, adiponectin-expressing Treg cells were incorporated into the cytoplasm of MDA-MB-157 cells. In other words, adiponectin-expressing Treg cells exhibited cell-in-cell binding to MDA-MB-157 cells. Furthermore, as shown in Figure 10d, cell death was observed in MDA-MB-157 cells 64 hours after the start of coculture of adiponectin-expressing Treg cells and MDA-MB-157 cells. The arrows in FIG. 10d indicate the remains of dead cells.

[0095] 5-3. Adiponectin-expressing Treg cells and MDA-MB-157 cells were co-cultured, and the cells were immunostained 16 hours after the start of co-culture. Images taken with a confocal laser scanning microscope (Leica) are shown in Figures 10e-g. For immunostaining, DAPI (blue), fluorescently labeled rabbit anti-adiponectin antibody (green) (GeneTex), and LuminiCell Tracker™ 540 (red) (Merck) were used. In Figures 10e-g, blue indicates the nucleus, green indicates the adiponectin-expressing Treg cells, and red indicates the cytoplasm of MDA-MB-157 cells.

[0096] Adhesion of adiponectin-expressing Treg cells to MDA-MB-157 cells was confirmed, as indicated by the arrowhead in Figure 10e. Cytoplasmic integration of adiponectin-expressing Treg cells with MDA-MB-157 cells was also confirmed, as indicated by the arrow in Figure 10e. Figure 10f shows a horizontal intracellular image, and Figure 10g shows a vertical intracellular image of the same subject as Figure 10f. Immunostaining also confirmed the incorporation of adiponectin-expressing Treg cells into MDA-MB-157 cells.

[0097] 5-4. Adiponectin-expressing Treg cells were co-cultured with MDA-MB-231 cells, and the cells were immunostained 16 hours after the start of co-culture. Images taken with a confocal laser scanning microscope (Leica) are shown in Figures 10h and 10i. Immunostaining was performed as in Test Example 1-3. The red color indicates the cytoplasm of MDA-MB-231 cells. As indicated by the arrows in Figures 10h and 10i, it was confirmed that adiponectin-expressing Treg cells were incorporated into MDA-MB-231 cells, as in MDA-MB-157 cells.

[0098] 5-5. Summary These results demonstrate that adiponectin-expressing Treg cells can exhibit cell-in-cell activity against cancer cells and can induce cell death in cancer cells.

[0099] Test Example 6: Examination of the inhibitory effect of adiponectin-expressing Treg cells on intraperitoneal mesothelioma The present inventors investigated whether adiponectin-expressing Treg cells can also exert an anti-cancer effect in vivo.

[0100] Human mesothelioma MPM-1 cells 1x10 6 The cells were injected intraperitoneally into NOD / SCID mice. MPM-1 cells were prepared by the method described in Non-Patent Document 6.

[0101] Seven days after the injection of MPM-1 cells, the adiponectin-expressing Treg cells were treated with mitomycin C (10 μg / ml) for 2 hours and 15 minutes, washed with PBS(-), suspended in 0.5 mL of PBS, and injected intraperitoneally into the mice. The dose of adiponectin-expressing Treg cells was 1 × 10 6 Mice in the control group were intraperitoneally injected with 0.5 mL of PBS. Each group consisted of 5 mice.

[0102] The mitomycin C treatment is a treatment for suppressing the proliferation of adiponectin-expressing Treg cells in mice after administration, and is a technique commonly used in the technical field. Specifically, since the adiponectin-expressing Treg cells in this test example were derived from mice, if they were administered untreated to NOD / SCID mice, they might proliferate in the mice and affect the test results. This possibility can be eliminated by treating them with mitomycin C before administration. Since the adiponectin-expressing Treg cells after mitomycin C treatment were washed with PBS(-), no mitomycin C remained in the adiponectin-expressing Treg cells administered to the mice.

[0103] Twenty-one days after injection of MPM-1 cells, each mouse was dissected and the growth of intraperitoneal mesothelioma was observed. The results for the control group, which was not injected with adiponectin-expressing Treg cells, are shown in Figure 11a, and the results for the group, which was injected with adiponectin-expressing Treg cells, are shown in Figure 11b. In Figures 11a and 11b, arrows indicate intraperitoneal mesothelial tumors.

[0104] The intraperitoneal mesothelioma tumors were excised from each mouse and weighed. The total weight of the tumors (5 mice) was calculated for each group (±SD). The control group had a tumor weight of 2.24±0.66 g, while the adiponectin-expressing Treg cell-injected group had a tumor weight of 0.38±0.31 g. Student's t-test revealed a P<0.01.

[0105] These results demonstrated with statistical significance that adiponectin-expressing Treg cells suppress the growth of intraperitoneal mesothelioma.

[0106] Figure 11c shows a representative example from the control group, and Figure 11d shows a representative example from the adiponectin-expressing Treg cell-injected group. The arrow in Figure 11c indicates a mesothelioma nodule. Figure 11e shows a histological diagram of a mesothelioma nodule excised from the control group. The excised mesothelioma nodule was formalin-fixed, paraffin-embedded, sectioned, and stained with hematoxylin and eosin (HE). The upper image in Figure 11e shows an HE-stained specimen of a mesothelioma nodule from the control group, and the lower image shows an enlarged version. As shown in Figure 11e, the mesothelioma nodule exhibited vigorous infiltration and proliferation into the surrounding striated muscle tissue. While mesothelioma nodules exhibiting such vigorous proliferation were observed in the control group (Figures 11a and 11c), they were rarely observed in the adiponectin-expressing Treg cell-injected group (Figures 11b and 11d).

[0107] As shown in Figure 11e, mesothelioma cells proliferated in the mesothelioma nodules of the control group.The results shown in Figures 11c-e demonstrated that mesothelioma nodule formation was significantly suppressed in the group injected with adiponectin-expressing Treg cells.

[0108] These results demonstrate that adiponectin-expressing Treg cells can exert anti-cancer effects in vivo.

Claims

1. A composition for preventing and / or ameliorating cancer, comprising regulatory T cells that express adiponectin.

2. The composition described in claim 1, wherein the regulatory T cells exhibit a cell-in-cell phenomenon against cancer cells.

3. The composition of claim 1, wherein the regulatory T cells express HMW adiponectin.

4. The composition described in claim 2, wherein the cancer has a reduced expression level of adiponectin receptor.

5. The composition of claim 4, wherein the adiponectin receptor is T-cadherin.

6. The composition described in any one of claims 1 to 5, wherein the cancer is at least one selected from the group consisting of breast cancer, mesothelioma, bladder cancer, and intraperitoneal disseminated cancer.

7. The composition according to any one of claims 1 to 5, wherein the cancer is breast cancer and / or mesothelioma.

8. The composition of any one of claims 1 to 5, wherein the cancer is triple-negative breast cancer.

9. The composition according to any one of claims 1 to 5, which is a pharmaceutical composition.

10. A method for producing regulatory T cells that express adiponectin and that can proliferate in a culture system in the absence of thymic stromal cells, comprising: (A) a step of co-culturing regulatory T cells that express adiponectin with thymic stromal cells; and (B) a step of co-culturing the regulatory T cells that express adiponectin with the thymic stromal cells by reducing the ratio of the thymic stromal cells to the regulatory T cells at the start of the co-culture compared to the start of a previous co-culture.

Citation Information

Patent Citations

  • Adiponectin-expressing regulatory t-cell precursors, composition and methods thereof

    US20210008117A1